AU2011222739A1

AU2011222739A1 - Collagen gel for bonding porous collagen- based materials with non- porous collagen- based materials

Info

Publication number: AU2011222739A1
Application number: AU2011222739A
Authority: AU
Inventors: Simon Kew; Tim Mead; Neil Rushton
Original assignee: Tigenix Ltd
Current assignee: Tigenix Ltd
Priority date: 2010-03-05
Filing date: 2011-03-07
Publication date: 2012-09-20
Also published as: WO2011107807A2; US20130197662A1; JP2013521036A; WO2011107807A3; CN103025841A; GB201003656D0; EP2542639A2; US9402709B2; CA2792022A1

Abstract

The invention discloses a process for fabricating a biomaterial, comprising: a) joining a porous collagen based-material with a non-porous collagen based- material by applying a controlled amount of a bonding layer of a gel comprising collagen to a bonding surface of the non-porous collagen based-material, and contacting a surface of the porous collagen based-material with the gel applied to the bonding surface to partially hydrate a section of the porous material at the interface between the materials; b)drying the gel to dry to bond the materials together; and c)cross-linking the collagens in the bonding layer. Also disclosed are biomaterials and implants produced using the fabrication process.

Description

WO 2011/107807 PCT/GB2011/050439 1 Fabrication process The present invention relates to a method for fabrication of biomaterials that can be used as tissue regeneration scaffolds in clinical applications requiring the repair of 5 damaged tissues. Specifically, the invention relates to a new fabrication process for joining porous and non-porous biomaterials to create new biomaterial formats having both porosity and mechanical strength. Porous collagen-based biomaterials are commonly used as scaffolds for the repair 10 and regeneration of damaged tissues, utilising their porous structure to enable cellular growth, proliferation, migration and infiltration into a defect site. Whilst porous collagen-based biomaterials are limited by substantial mechanical weakening caused by the existence of pores in the material, these pores are necessary in order to promote cellular proliferation and infiltration during the degradation process following 15 implantation thus allowing the material to mediate (i.e. provide a scaffold for) the regeneration of damaged tissues. The inherent mechanical weakness of porous materials means (i) they cannot be fixed or anchored in place using conventional fixation techniques such as suturing and (ii) they cannot be used to mimic or repair load bearing tissues which have inherent mechanical strength, for example tendons 20 and ligaments. Furthermore, their porosity limits their ability to be used to contain biological species such as biomolecules or cells which may be utilised for pharmacological effect. Collagen scaffolds have traditionally been limited to being either porous but weak structures or dense but strong structures. 25 Combining a porous collagen-based material with a mechanically strong non-porous collagen-based material potentially provides scaffolds for regeneration of tissues where both mechanical strength and porosity are required. There are several WO 2011/107807 PCT/GB2011/050439 2 applications for orthopaedic repair and in dental medicine where the ability to combine these materials into a single structure would be advantageous. The bone-soft tissue interface is difficult to regenerate using biomaterials which 5 provide a scaffolding matrix for the development of new tissue due to the structural differences between the different tissue types. The ideal scaffold for this application would be capable of directing the regeneration of isotropic tissues requiring extensive vascularisation (e.g. cancellous bone) and mimicking avascular tissues, such as tendon, ligament and fibrocartilage, where mechanical strength in an orientation is 10 more important. A suitable scaffold would require a combination of different materials types because porous materials, particularly those composed of collagen, have inadequate mechanical properties for load bearing applications and furthermore are not aligned. 15 US 5,171,273 discloses processes for fabricating biocompatible collagen grafts having high tensile strength. EP0639959 B1 discloses a prosthetic ligament manufactured by braiding cross linked low density collagen filaments with high density filaments. 20 Combination of porous and non-porous collagen-based materials enables the production of a material that can provide a substantially permeable and a substantially impermeable compartment. Thus this material structure is designed to provide the capability to sequester and selectively deliver biologically relevant 25 species such as cells and biomolecules to tissue defect sites. The ability to fabricate biomaterials with both a permeable and an impermeable compartment is also required in applications where the delivery of a therapeutic agent such as cells or proteins is required without premature loss of such agents via diffusion or WO 2011/107807 PCT/GB2011/050439 3 hydrodynamic flow, such as that found in a synovial joint. The current state of the art for the combination of porous and non-porous materials for filling defects in sites relevant to orthopaedic and dental medicine involves the use of separate porous and non porous components. For example, dental tooth extraction sockets can be filled 5 using a porous bone void filler and are then isolated using a substantially impermeable membrane. It would be advantageous to use a contiguous biomaterial having both porous and non-porous properties. It is known to use collagen in glues to join biomaterials together because it is capable 10 of solidifying and then being reabsorbed, and it is biocompatible. Collagen as such, however, has weak adhesive power. US 2008/0295735 discloses a glue comprising a mixture of collagen and a cross-linking agent of the aldehyde type or a modified collagen with aldehyde functions and presented in lyophilised form. 15 Whilst combining porous collagen-based materials (with low mechanical strength) and non-porous collagen-based materials (with high mechanical strength) would provide new and advantageous biomaterial formats, the main problem with fabricating "hybrid" collagen-based biomaterials (i.e. those having porosity and mechanical strength) is that the components are not readily integrated, and do not 20 bond well because known glues are weak and invariably require a chemical cross linking treatment which can result in the creation of cytotoxic by-products. The present invention seeks to overcome the problems associated with prior art methods and materials by providing a method to fabricate a biomaterial that provides the functionality of both porous and non-porous materials in a single contiguous material, 25 thus enabling porosity to be combined with mechanical strength. According to a first aspect of the present invention, there is provided a process for fabricating a biomaterial, comprising WO 2011/107807 PCT/GB2011/050439 4 a) joining a porous collagen based-material with a non-porous collagen based material by applying a controlled amount of a bonding layer of a gel comprising collagen to a bonding surface of the non-porous collagen based-material, and contacting a surface of the porous collagen based-material with the gel applied to the 5 bonding surface to partially hydrate a section of the porous material at the interface between the materials; b) drying the gel to dry to bond the materials together; and c) cross-linking the collagens in the bonding layer. 10 The term "biomaterial" as used herein means a material that is biocompatible with a human or animal body. The term "porous" as used herein means that the material may contain macropores and/or micropores. The fabricated biomaterial of the invention is defined as contiguous because previously separate non-porous and porous collagen-based materials lie adjacent each together after fabrication. The 15 fabricated biomaterial is also defined as continuous, because the collagens in the respective porous and non-porous materials are bonded to the collagen in the bonding layer of gel at one or more interfaces to create a bonded and integrated biomaterial having the functionality and properties of each of the component materials. 20 In order to assemble a fixed spatial configuration of porous and non-porous materials it has been identified that dispensing controlled amounts of a gel comprising collagen may be used to bond the materials together. Collagen gels are commonly used to form cast structures however, their use in methods to bond porous and non-porous 25 materials has not been achieved to date. Use of inadequate or excessive amounts of collagen gel to adhere the materials results in several deleterious effects on the fabricated biomaterial. The ability to adhere the materials using a controlled way in which to dispense the collagen gel is key to the assembly of the collagen materials WO 2011/107807 PCT/GB2011/050439 5 used within the process. The joining step is preferably carefully controlled in order to ensure that the porosity of the porous collagen-based material is not compromised when the gel is applied. The joining step and the quality of the resulting bond may be controlled by using a controlled amount of gel with a known viscosity. A controlled 5 amount of gel is defined as the amount which is sufficient to only partially hydrate a section of the porous collagen-based material at the planned interface between the porous and non-porous materials. The applicant has determined that porous and non-porous collagen-based materials can be bonded using a bonding layer of between 50-100 pm in thickness. The amount of collagen gel applied in the bonding 10 layer may be between 50-500 pL cm 2 . If the amount of collagen gel used is too high, the porosity of the porous component is compromised by the capillary uptake of collagen gel into the porous component. Applying too much gel thus over-hydrates the porous collagen-based material, eliminating the pore structure and damaging the quality of the biomaterial produced using the process. Conversely, using too little gel 15 results in insufficient infiltration of the gel into the porous collagen based-material, providing an incomplete bond, resulting in insufficient adhesion between the materials and leading to gaps being present between the materials which create regions of structural weakness and which disadvantageously impact on the mechanical strength of the resulting biomaterial. 20 The term "gel" encompasses viscous solutions and compositions comprising collagen, which may exhibit flow when in the steady-state. The gel preferably has adhesive or cohesive properties and may be considered as a glue. The viscosity of the gel is preferably controlled in order to ensure optimum infiltration and hydration of 25 the porous collagen-based material at the planned interface. The viscosity of the gel may be between1-250,000 cP, for example 10, 100, 1000, 10,000, 25,000, 50,000, 100,000, 150,000 or 2000,000 cP. A lower viscosity can result in too much infiltration of the gel into the porous collagen based-material, resulting in an undesirable amount WO 2011/107807 PCT/GB2011/050439 6 of hydration, which can eliminate the pore structure. A higher gel viscosity can result in insufficient infiltration, which can cause a weak bond between the materials. The concentration of collagen in the gel may be between 0.1-2% wt/vol. The gel may 5 comprise 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% or 2% wt/vol collagen. The collagen may be Type I collagen, Type || collagen, Type Ill collagen, Type IV collagen, gelatin, agarose, cell-contracted collagen containing proteoglycans, glycosaminoglycans or glycoproteins, fibronectin, laminin, elastin, fibrin, synthetic 10 polymeric fibres made of poly-acids such as polylactic, polyglycolic or polyamino acids, polycaprolactones, polyamino acids, polypeptide gel, copolymers thereof and/or combinations thereof. The collagen may derive telo-containing collagen, atelo collagen, or derivatised collagen, or a combination thereof. The term collagen as used herein encompasses recombinant human (rh) collagen. The collagen may be 15 soluble or insoluble and may be derived from any tissue in any animal and may be extracted using any number of conventional techniques. Step (b) may comprise air drying. Air drying may form weak non-covalent interactions between the porous and non-porous materials that withstand rehydration due to the 20 insolubility of the components of the gel. The temperature and/or humidity of the environment surrounding the biomaterial may be controlled to control the drying rate. Drying a collagen structure in air may cause structural distortions due to the variation in drying rate within the structure, this leading to a physical shape that may not be fit for purpose. In drying step (b) the structure/shape of the materials is preferably 25 substantially retained without distortion. This is important to avoid a decrease in quality of any fabricated biomaterial, which invariably has to precisely fit into defect sites in patients, and where appropriate must have uniform planarity and laminar structure, with minimal or no undesired distortion. The amount of distortion upon WO 2011/107807 PCT/GB2011/050439 7 drying is influenced by the degree of hydration of the materials when they are joined together. Beyond the deleterious effects of loss of pore structure, excessive hydration should be also avoided - by using only sufficient gel to ensure bonding of the porous and non-porous collagen-based materials - to minimise distortion upon drying. Thus, 5 distortion may be minimised by using only sufficient gel to ensure bonding of the materials. The importance of controlling the shape/structure of a fabricated biomaterial during the fabrication process has led the applicant to develop methods to ensure that the 10 desired structure, shape, planarity, and laminarity of the biomaterial is retained as it dries. The structure/shape etc. of the biomaterial may be retained by constraining the biomaterial in a cage, mould, press or frame to minimise structural distortion as it dries. Where the biomaterial has a planar or laminar structure the structure/shape may be retained by sandwiching the biomaterial between rigid sheets as it dries. The 15 structure/shape may be retained by adhering or attaching a surface other than the bonding surface of the non-porous material to a substrate. The cage, mould, press, frame, rigid sheets, and/or substrate is preferably metallic or manufactured from a material sufficiently rigid to constrain/prevent distortion of the drying biomaterial. The cage, mould, press, frame, rigid sheets, and/or substrate may comprise or be coated 20 with a non-stick material, for example polytetrafluoroethylene. Collagens are provided by each of the porous and non-porous collagen-based materials, as well as in the bonding layer of gel comprising collagen. The cross linking step is preferably employed to cross-link or bioconjugate the collagens in the 25 bonding layer with those provided by the porous and non-porous collagen-based materials. Because the collagen applied at the interface between the materials partially hydrates an inwardly extending section of the porous collagen based material, the cross-linking further joins the collagen based-material and the non- WO 2011/107807 PCT/GB2011/050439 8 porous collagen based-materials by providing covalent cross-inking to the interfacial structure. The cross-linking step may also cross-link collagens in the porous collagen based-material, and in the non-porous collagen based-material. Cross-linking provides added stability and renders the collagen molecules resistant to collagenase 5 and other matrix metalloprotease activity in vivo. The cross-linking step may comprise the use of one or more suitable chemical or biological agents or physical cross-linking methodologies with the proviso that the cross-linking does not require that the biomaterial is washed to remove potentially cytotoxic end- or by-products, such as aldehydes, a step which risks fully hydrating the biomaterial and causing 10 undesirable loss of pore structure and/or distortion of structure/shape upon drying. The cross-linking may be a combination of physical and/or chemical/biological methodologies. The gel preferably comprises components which can facilitate the cross-linking of the 15 collagens in the bonding layer. The gel may further comprise a glycosaminoglycan (GAG) or mucopolysaccharide. Glycosaminoglycans are a family of macromolecules containing long unbranched polysaccharides containing a repeating disaccharide unit. Preferably, the glycosaminoglycan is selected from one or more of chondroitin sulphate, dermatin sulphate, heparin, heparin sulphate, keratin sulphate and 20 hyaluronic acid. Chondroitin sulphate may be chondroitin-4- sulphate or chondroitin 6-sulphate, both of which are commercially available, for example, from Sigma Aldrich Inc. The chondroitin-6-sulphate may be derived from shark. The GAG may be used at 0.01 to 12 (dry)wt%, or 1 to 5.5 (dry) wt%, or 1.8 to 2.3 (dry) wt%. Preferably the GAG is used at 0.1% wt/vol. The gel may comprise other polysaccharides or 25 other components which can provide cross-linking functionality. The composition of the gel may be the same as the composition of the porous and/or non-porous collagen-based material. The concentration of the collagen and GAG in the gel may WO 2011/107807 PCT/GB2011/050439 9 be the same as the concentration of the collagen and any GAG in the porous collagen-based material. Various physical cross-linking methodologies may be used to cross-link the collagens 5 in the bonding layer. The cross-linking step may comprise a dehydrothermal (DHT) treatment applied to the dried biomaterial to provide a condensation reaction which bonds amine and carboxylic acid groups. The advantage of DHT treatment is that no chemical reagent is required and no potentially cytotoxic end or by-products are created during the treatment. The biomaterial may be heated in a vacuum. The 10 temperature and exposure period of the DHT treatment may be varied to alter the compressive and tensile properties and cross-linking density of the biomaterial. The temperature of the DHT treatment may be between 60-180 degrees Celsius, with an exposure between 24-120 hours. The vacuum may be e.g. 50-150 mTorr. 15 The cross-linking may be photo-induced. The cross-linking step may comprise UV or visible light treatment. UV irradiation (at 254 nm) is a rapid and easily controlled means of increasing the mechanical strength of collagen fibres and does not produce any toxic by-products which require subsequent removal by washing the biomaterial. The collagen gel may comprise hydroxyl containing components such as 20 polysaccharides or GAGs, which may optimise the UV cross-linking treatment. The collagens may be cross-linked using visible light in the presence of photosensitiser dyes such as methylene blue and rosebengal. The cross-linking step may comprise DHT treatment and UV treatment, or a 25 combination of cross-linking methodologies. The cross-linking step may comprise radiation treatment, using electron beam (EB) or gamma rays. Consistent with the majority of the physical cross-linking WO 2011/107807 PCT/GB2011/050439 10 methodologies, radiation-induced cross-linking does not require the use of cytotoxic cross-linkers and no subsequent treatment steps are necessary. Another advantage of radiation-induced cross-linking is that gamma rays can penetrate the biomaterial to depths that may not be achieved using other methodologies such as visible light or 5 UV light-induced cross-linking. Whilst physical cross-linking methodologies advantageously do not result in the formation of cytotoxic end- or by-products, one or more chemical cross-linking agents, preferably used in the vapour phase, can be employed to cross-link the 10 collagens in the bonding layer. Chemical cross-linking reagents are molecules that contain two or more reactive ends capable or chemically attaching to specific functional groups (primary amines, sulfhydryls, etc.) on proteins. Preferably, the chemical cross-linking agent should not result in the formation of non-volatile side products. The vapour phase chemical cross-linking agents may be selected from the 15 group consisting of: glutaraldehyde, formaldehyde, and hexamethyldiisocyanate. The cross-linking agent may be selected from the group consisting of: carbodiimides, polyaldehydes, polysulfones, activated PEGs, epoxides, imidazoles and diisocyanates. The cross-linking step may comprise treatment with an aldehyde such as glutaraldehyde or formaldehyde (which can cross-link lysine residues), 1-ethyl-3 20 (3-dimethyl amino propyl) carbodiimide hydrochloride (EDC) (which can cross-link amino and carboxyl groups), or polyepoxy compounds such as glycerolpoly(glycidylether) and poly(ethyleneglycoldiglycidylether). The cross-linking agent may be hexamethylene diisocyanate (HMDI), which can cross-link amino groups. EDC is a preferred cross-linking agent because it does not become part of 25 the final cross-link between collagen molecules. The gel may further comprise components (e.g. GAGs) that are modified or derivatised to comprise reactive groups that react with the non-porous and porous WO 2011/107807 PCT/GB2011/050439 11 collagen materials to achieve cross-linking without the release of potentially cytotoxic by- or end-products. The components may be chemically functionalised with aldehyde reactive groups or NHS activated ester groups. The components may be triazine activated collagen or epoxide functionalised collagen. 5 The gel may be acidic or alkaline prior to being applied to the bonding surface. The gel may gelate at neutral pH. The pH of the gel may be neutralised upon application to the bonding surface. The gelation time of the gel may be 1-60 minutes after neutralisation. Cross-linking may occur as the pH of the gel neutralises after 10 application, causing fibrillogenesis in the gel, i.e. the development of fine fibrils normally present in collagen fibres of connective tissue. As collagen contains both nucleophilic and electrophilic groups it is can self-cross link using many of the chemistries described above. In a preferred embodiment a gel 15 is used in which intergel cross-linking reactions are prevented or minimised thereby allowing a cross-linking gel to be applied without premature strengthening of the gel. The gel may comprise collagen in combination with polyethylene glycol and/or glycosaminoglycans. 20 In the fabrication process one or more pieces or regions of non-porous collagen based material may be joined to one or more pieces or regions of porous collagen based material. As will be described below the process can be used to fabricate novel biomaterial formats which comprise multiple regions of porous and non-porous collagen-based material. The formats may mimic the composition and/or structure of 25 tissues including bone, cartilage, tendon, ligament and the interfaces between these tissues.

WO 2011/107807 PCT/GB2011/050439 12 According to a second aspect of the present invention there is provided a fabricated biomaterial comprising porous and non-porous collagen-based materials bonded with a bonding layer of dried gel comprising collagen. The biomaterial may be multi-phase and may be continuous. The fabricated biomaterial of the invention is defined as 5 multiphase because it comprises both porous and non-porous collagen-based materials, i.e. one or more phases having a required porosity and one or more phases having required mechanical strength. The invention may also utilise a novel cross linking sequence in order to achieve the 10 construction of a multiphase biomaterial which comprises both non-porous and porous collagen-based materials. The porous and non-porous collagen-based materials may further comprise other biopolymeric components such as glycosaminoglycans (e.g. chondroitin 4-sulfate, 15 chondroitin 6-sulfate, keratan sulfate, dermatan sulfate, heparan sulfate, hyaluronic acid or chitosan), proteoglycans (e.g. decorin), proteins (e.g. elastin, resilin or other components of the extracellular matrix). One or both of the porous and non-porous collagen-based materials may be cross 20 linked prior to being joined together. Cross-linking of the separate components provides mechanical strength which can improve the physical and mechanical properties of a biomaterial fabricated by the process of the invention. Preferably, at least the porous collagen-based material is cross-linked prior to being employed in the fabrication process. This ensures that the material does not weaken, break-up or 25 disintegrate upon rehydration by the bonding layer of gel. The porous collagen-based material may be unmineralised or mineralised. In embodiments where one or more phases, pieces, or regions are required to mimic WO 2011/107807 PCT/GB2011/050439 13 bone, the porous collagen-based material may be mineralised and may comprise a calcium phosphate, for example brushite, octacalcium phosphate, apatite hydroxyapatite, P-tricalcium phosphate, biphasic calcium phosphate, substituted calcium phosphate, silicate-substituted calcium phosphate, silicate-substituted 5 hydroxyapatite, or silicate-substituted tricalcium phosphate. The porous collagen based material may comprise a co-precipitate of collagen and glycosaminoglycan or calcium phosphate, or a triple co-precipitate of collagen, glycosaminoglycan and a calcium phosphate material. The collagen and the one or more glycosaminoglycans may be cross-linked. 10 The percentage of open-cell porosity (measured as a percentage of the total number of pores both open- and closed-cell) in the porous material is preferably from 1 to 100%, more preferably from 20 to 100%, and still more preferably from 90 to 100%. 15 The collagen is preferably present in the material in an amount of from 5 to 90 (dry) wt%, more preferably from 15 to 60 (dry)wt%, more preferably from 20 to 40 (dry) wt%. The one or more glycosaminoglycans may be present in the material in an amount of 20 from 0.01 to 12 (dry)wt%, more preferably from 1 to 5.5 (dry) wt%, most preferably from 1.8 to 2.3 (dry) wt%. Preferably, the ratio of collagen to the total amount of one or more glycosaminoglycans is from 8: 1 to 30: 1 by weight (dry), more preferably from 10: 1 to 30: 1 by weight (dry), still more preferably 10: 1 to 12: 1 by weight (dry), and most preferably 11: 1 to 23: 2 by weight (dry). 25 The bonding layer may be between 50-100 pm (microns) in thickness.

WO 2011/107807 PCT/GB2011/050439 14 The collagens in the bonding layer may be cross-linked. The collagen in the porous and/or non-porous collagen-based materials may be cross-linked. The biomaterial may be cross-linked to provide multiple different mechanical and/or degradation characteristics. The collagen and the glycosaminoglycan in the porous or non-porous 5 collagen-based materials may be cross-linked. Due to the controlled amount of hydration of the porous collagen-based material in the fabrication process, the biomaterial advantageously retains >95% of the original porosity of the porous collagen-based material. 10 The non-porous collagen-based material may comprise an extruded collagen sheet or membrane, or collagen fibres (e.g. in a bundle), which may be extruded and/or aligned. Extruded collagen structures, including fibres (both woven and non-woven) and sheets, reconstituted from insoluble and soluble collagen are well known to 15 those skilled in the art, as are porous materials based on collagen and a range of combined biopolymeric materials. However, their usage in combination has been limited due to that inability to successfully integrate these materials into single structures. The non-porous collagen may also be a purified animal or human derived tissue, such as decellularised skin, intestine, periosteum, pericardium, fascia or other 20 xenograft or allograft sheets that are well known to those skilled in the art. The biomaterial may be an unmineralised porous patch comprising a non-porous collagen membrane bonded to a porous collagen-based material comprising collagen and a GAG. The unmineralised porous patch may comprise more than one region of 25 the porous collagen-based material, and it is envisaged that patches of various shapes/sizes can be fabricated using the method of the present invention. The non porous collagen-based material may overlap the porous collagen-based material to provide a flap to enable fixation of the device in a defect site of a patient. The fixation WO 2011/107807 PCT/GB2011/050439 15 may be achieved by using techniques known to those skilled in the art such as suturing, tacking, use of darts, use of composite devices such as devices comprising sutures and polymeric tabs or buttons, suture passing devices, bioadhesives such as fibrin glues, techniques involving the induction of fibrin clots or techniques based on 5 the formation of adhesives from other autologous body fluids. The non-porous collagen-based material may act as a barrier to the transport of cells, proteins, and small molecules out of the porous collagen-based material. 10 The porous collagen-based material may comprise a porous collagen scaffold and the non-porous collagen-based material may comprise aligned collagen fibres. The biomaterial may comprise multiple regions of porous and/or nonporous collagen based materials. The biomaterial may comprise non-porous aligned collagen fibres having a porous mineralised collagen-based material at each end. 15 There is provided a fabricated biomaterial produced by the process according to the first aspect of the invention. According to a further aspect of the present invention, there is provided an implant 20 comprising the fabricated biomaterial of the invention. The implant may comprise one or more phases, pieces or regions of porous and/or non-porous collagen-based material. According to a further aspect of the present invention, there is provided a synthetic 25 cartilage, bone, ligament, tendon, meniscus, periodontal tissue, dentine, enamel, intervertebral disc, annulus fibrosus, or nucleus pulposus implant, graft, substitute, scaffold, filler, coating or cement comprising a biomaterial or implant according to the present invention.

WO 2011/107807 PCT/GB2011/050439 16 The biomaterial or implants comprising the biomaterial of the invention may further comprise cells. The cells may be stem or progenitor cells, differentiated cells, terminally differentiated cells, or combinations thereof. The cells may be totipotent, 5 pluripotent or unipotent stem cells, or induced pluripotent stem cells. The cells may be human embryonic stem cells, derived via a technology which does not necessitate the destruction of the human embryo, for example via an established cell line. Mesenchymal stem cells (also referred to as marrow stromal cells, multipotent stromal cells, or MSCs) are pluripotent stem cells which can differentiate into a 10 variety of cell types including osteoblasts, tenocytes, chondrocytes, myocytes, adipocytes. These cell types have the ability to generate bone, tendon, ligament, cartilage, muscle, and fat. The cells may be MSCs or any cell within the MSC lineage. Progenitor cells can go through several rounds of cell division before terminally differentiating into a mature cells, and the cells may be these intermediary 15 cells. The cells may be selected from the group consisting of: MSCs (marrow stromal cells, mesenchymal stem cells, multipotent stromal cells), chondrocytes, fibrochondrocytes, osteocytes, osteoblasts, osteoclasts, synoviocytes, adipocytes, bone marrow cells, mesenchymal cells, stromal cells, genetically transformed cells, or combinations thereof. The cells may be autologous or heterologous. 20 The cells may include one or more of the following: embryonic stem cells; precursor cells derived from adipose tissue; peripheral blood progenitor cells; stem cells isolated from adult tissue; genetically transformed cells; a combination of chondrocytes and other cells; a combination of osteocytes and other cells; a 25 combination of synoviocytes and other cells; a combination of bone marrow cells and other cells; a combination of mesenchymal cells and other cells; a combination of stromal cells and other cells; a combination of stem cells and other cells; a combination of embryonic stem cells and other cells; a combination of precursor cells WO 2011/107807 PCT/GB2011/050439 17 isolated from adult tissue and other cells; a combination of peripheral blood progenitor cells and other cells; a combination of stem cells isolated from adult tissue and other cells; and a combination of genetically transformed cells and other cells. 5 Using the above-described fabrication process it is possible to combine collagen sheets, fibres with mineralised and non-mineralised porous components thus enabling the fabrication of a number of different configurations and formats that mimic the structure of human tissues. Some of the applications of the biomaterials produced using the recited fabrication process are detailed below. 10 In one embodiment the biomaterial may simulate a bone-tendon insertion structure known as Sharpey's Fibres, essentially a matrix of connective tissue comprising bundles of strong collagenous fibres connecting periosteum to bone. The biomaterial comprising substantially parallel non-porous collagen fibres (parallel along the long 15 axis of the implant) and further comprising a porous mineralised collagen-based material at one or both ends (i.e. one or two regions of porous collagen-based material comprising collagen, a GAG and calcium phosphate). The biomaterial may comprise loops suitable for suturing at each end. 20 In another embodiment, the biomaterial may be used to fill a defect in the meniscus. The meniscal implant can be designed to fit into the defect site and fixed in place by standard techniques such as suturing, tacking, use of darts, use of composite devices such as devices comprising sutures and polymeric tabs or buttons, suture passing devices, bioadhesives such as fibrin glues, techniques involving the 25 induction of fibrin clots or techniques based on the formation of adhesives from other autologous body fluids. The suturing may be done through the porous part of the device and/or the non-porous part as appropriate, in order to fix the device in place.

WO 2011/107807 PCT/GB2011/050439 18 In a further embodiment, the biomaterial may be used as an arterial closure device. The device can be designed such that the porous part fits into the artery and the non porous part folds over and around the artery in a manner to provide closure. The device can then be fixed in place by any standard techniques such as suturing, 5 tacking, use of darts, use of composite devices such as devices comprising sutures and polymeric tabs or buttons, suture passing devices, bioadhesives such as fibrin glues, techniques involving the induction of fibrin clots or techniques based on the formation of adhesives from other autologous body fluids. The suturing may be done through the porous part of the device and/or the non-porous part as appropriate, in 10 order to fix the device in place. Patches for the regeneration of articular cartilage can be fabricated, these utilising the porous material to deliver cells or (macro)molecular species whereas the non porous material enables fixation to surrounding tissues and prevents loss of 15 components loaded into the porous material. The patches can be fabricated based on a combination of a porous collagen sheet with a collagen based fibre construct, such as a fabric, which provides suturability. Alternatively, a combination of a porous collagen sheet, such as an extruded collagen sheet, can be combined with a non porous collagen sheet, which provides suturability and impermeability. In one 20 embodiment an implant is provided which comprises an unmineralised porous patch, i.e. a porous collagen-based material comprising collagen and a GAG bonded to a non-porous collagen sheet. This structure is of particular utility as a scaffold for enhancement of a chondral stimulation technique known as microfracture, where puncturing sub chondral bone is utilised to generate fibrocartilage to cover chondral 25 defects. In addition, this material structure is particularly useful in the application of autologous chondrocytes implantation procedures, where chondrocytes are implanted into chondral defects in articular cartilage. A specific advantage of this material, if utilised for a matrix-assisted autologous chondrocytes implantation WO 2011/107807 PCT/GB2011/050439 19 procedure is that the porous layer can deliver a cell-loaded porous material that closely conforms to the defect shape. Biomaterials and implants for regeneration of tendons and ligaments can be 5 fabricated, using (i) a mineralised and non-mineralised material combination which mimics the bone-tendon interface, or (ii) a porous collagen sheet combined with a non-porous bundle of collagen fibres to provide a material that can be used to augment tendon regeneration. Patches for the repair of bone-ligament/tendon interfaces can be fabricated using porous mineralised calcium phosphate collagen 10 blocks combined with a non-porous bundle of collagen fibres. The fabrication process of the invention may comprise fabricating the formats described herein, by joining non-porous collagen-based material to porous collagen based material, as described previously. 15 There is provided a use of a collagen gel to bond porous and non-porous collagen based materials. According to a further aspect of the present invention there is provided a method of 20 treatment of a defect in a target tissue of a patient comprising: taking a biomaterial or implant according to the present invention and inserting the material into the defect of the patient. According to a further aspect of the present invention there is provided a method of 25 organ or tissue engineering in a patient, comprising the step of replacing a target tissue in the patient with a biomaterial or implant according to the present invention.

WO 2011/107807 PCT/GB2011/050439 20 According to a further aspect of the present invention there is provided a use of a biomaterial or implant according to the present invention to treat a defect in a target tissue of a patient. There is provided a use of a biomaterial or implant according to the present invention in the manufacture of a medicament to treat a defect in a target 5 tissue of a patient. There is provided a use of a biomaterial or implant according to the present invention in tissue engineering of a target tissue of a patient. There is provided a use of a biomaterial or implant according to the present invention in the manufacture of a 10 medicament to tissue engineer a target tissue of a patient. The target tissue may be selected from the group consisting of: cartilage, bone, ligament, tendon, artery, Sharpey's fibres, meniscus, periodontal tissue, dentine, enamel, intervertebral discs, annulus fibrosus, and nucleus pulposus. 15 The patient may be a mammal, or a non-human mammal. The patient may be a human, dog, camel, or horse. According to a further aspect of the present invention there is provided a kit of parts 20 comprising a biomaterial or implant according to the present invention, in combination with a delivery device. The kit may comprise a plurality of biomaterials, implants, delivery devices, or combinations thereof. The kit may further comprise additional tools which may be required in procedure utilised to deliver the implant, or engineer the tissue or organ. 25 The present invention will now be described further by way of example and with reference to the following drawings in which: WO 2011/107807 PCT/GB2011/050439 21 Figure 1: shows a schematic detailing the process for the controlled gel bonding of porous and non-porous collagen-based materials components; Figure 2: shows the configuration of a three-region multiphase implant suitable for the regeneration of fibrous connective tissue with bone; 5 Figure 3a: shows a two-layer tissue repair membrane; Figure 3b: shows the structure of a two-layer tissue repair membrane under scanning electron microscope; Figure 4a: shows an assembly of multiple different shapes and sizes of porous collagen on an extruded collagen sheet; 10 Figure 4b depicts the use of the product in treatment of a defect in a tissue; Figure 5a: shows a schematic for placing an implant at a defective site on the meniscus; Figure 5b: shows a cross-section of the meniscal implant fixed in position by sutures; Figure 6a: shows a schematic for use of the product as an arterial closure device, 15 and Figure 6b: shows a cross-section of the arterial closure device fixed in position by sutures. Materials 20 Collagen: Type 1, microfibrillar collagen from bovine tendon, Integra Life Sciences Plainsboro, NJ, USA GAG: Chondroitin-p-sulphate from shark cartilage, sodium salt, Sigma-Aldrich Inc (St. Louis, MO, USA) Calcium Sources: (i) Calcium hydroxide (Ca(OH)2), Sigma- Aldrich Inc (St. Louis, MO, USA); (ii) Calcium nitrate (Ca (NO3) 2.4H2O) , Sigma-Aldrich Inc (St. Louis, MO, USA) Phosphorous Source: 25 Orthophosphoric acid (H3PO4), BDH Laboratory Supplies (Poole, United Kingdom) Cross-linking Agents: 1-Ethyl-3- (3-Dimethylaminopropyl) Carbodiimide (=EDAC) , Sigma-Aldrich Inc (St. Louis, MO, USA); N-Hydroxysuccinimide (=NHS) , Sigma Aldrich Inc (St. Louis, MO, USA).

WO 2011/107807 PCT/GB2011/050439 22 Referring to Figure 1, the schematic shows the preferred method of fabrication which comprises a sequence of steps which can be applied in whole or in part, to produce the fabricated biomaterials of the invention. The initial steps involve hydrating a non 5 porous collagen-based material (10), most preferably an extruded sheet or membrane, or a bundle of fibres, with a bonding layer of a collagen-based gel. The non-porous material (10) is dosed with a specific amount of the gel, typically 50-500 pL cm- to ensure that the resulting bond is of an appropriate thickness for bonding the materials together, and which is not so excessive as to damage the porosity or 10 create distortion problems upon subsequent drying. The inventors have experimentally determined that an appropriate thickness of the bonding layer is 50 100 pm. In step (iii) the hydrated non-porous material (20) is then joined to the porous collagen-based material (30) by gently pressing the porous collagen-based material (30) onto the hydrated non-porous material (20) so as to contact the bonding 15 layer of gel (40). The capillary forces at the interface between the materials (20, 30) draw a limited amount of the gel into the porous collagen-based material (30) resulting in partial hydration of a narrow section of the porous collagen-based material (30) at the interface between the two materials. Preferably, the porous collagen-based material is cross-linked to provide mechanical strength, and which 20 minimises the tendency of the material to weaken or disintegrate upon contact with the bonding layer of gel. Although not shown, multiple regions or pieces of porous collagen-based material can be joined to one or more regions or pieces of non porous collagen-based material. Step (iv) comprises drying the joined materials with minimal distortion to the physical structure (shape, size) to bond them together, to 25 form a fabricated continuous, multiphase biomaterial (50). Although not shown, the structure, shape, planarity, laminarity of the biomaterial is retained by minimising and ideally preventing distortion upon drying. This can be achieved by physically constraining the biomaterial, for example in a cage, mould or frame, or by inserting it WO 2011/107807 PCT/GB2011/050439 23 between rigid sheets, or by adhering the non-porous collagen-based material to a rigid non-distortable substrate. Preferably step (iv) comprises cross-linking the collagens and any other cross-linkable components in the gel to provide a stronger bond. Biomaterial (50) is defined as "continuous" because the two materials (10, 30) 5 are bonded and cross-linked together, and "multiphase" because the biomaterial comprises porous and non-porous regions having different functionalities and properties. Referring to Figure 2, the configuration of an implant suitable for the regeneration of 10 fibrous connective tissue with bone is shown. The implant consists of fabricated biomaterial (50) comprising non-porous region (60) and two porous regions (70). Non-porous region (60) comprises non-porous collagen-based material (10) in the form of extruded collagen. Porous regions (70) comprise porous mineralised collagen-based material (30) comprising collagen, a glycosaminoglycan and calcium 15 phosphate. The porous regions (70) are essentially blocks of mineralised collagen/GAG which mimic the structure of bone. The blocks can be attached to each end of the extruded collagen using a bonding layer of adhesive collagen gel (not shown). The collagens in the bonding layer of gel can be cross-linked to the collagens in the non-porous and porous collagen-based materials, for example via 20 DHT treatment. The implant can be anchored in bone at each end, and can be used to repair, replace or augment ligaments and tendons. The implant depicted in Figure 2 was fabricated as described below. An extruded collagen fibre was produced according to methods previously described, 25 for example in US 5,171,273. Insoluble or soluble collagen, extruded into an aqueous solution (pH -7.5, at 370C) produced a collagen fibre with sufficient mechanical strength to be processed. The extruded collagen fibre was spooled to provide a fibre structure which contains substantially parallel fibres along the long axis and contains WO 2011/107807 PCT/GB2011/050439 24 loops at the terminal ends, which provide suturable attachment points. The collagen fibre loop was then cross-linked via immersion in a cross-linking solution comprising N-hydroxysuccinimide (N HS) and 1 -ethyl-3-(3-dimethyllaminopropyl)carbodiimide (EDC) in MES buffer (pH 5.5) for one hour before being washed with deionised water 5 and air dried. The collagen fibre bundle was cast in a collagen-chondroitin-6-sulphate gel prepared via blending an acidified gel comprising 1g freeze dried collagen, 0.1 g chondroitin-6-sulfate and 100 mL 20 mM HCI. The amount of gel used was 50 pL per cm 2. The collagen-GAG gel was allowed to hydrate the fibre bundle and fill the interstitial apace between the fibres. No excess collagen/GAG gel was present. 10 The porous collagen-glycosaminoglycan-calcium phosphate material was prepared according to methods previously developed by the applicant (disclosed in WO 2005/051447, WO 2006/095154 and WO 2008/017858). The process described in WO 2005/051447 involves: providing an acidic aqueous solution comprising 15 collagen, a calcium source and a phosphorous source and a glycosaminoglycan; and precipitating the collagen, the brushite and the glycosaminoglycan together from the aqueous solution to form a triple co-precipitate. Beyond the use of the applicant's triple co-precipitated porous collagen-based material, it is envisaged that other porous collagen-based materials can be used in the fabrication method of the 20 invention to produce continuous fabricated multiphase biomaterials and implants having desired porosity and strength. After preparation, the porous material was cut using a scalpel or similar device to form bone blocks of the dimensions approximately 10 x 10 x 12 mm. 25 Before the collagen/chondroitin-sulfate gel was allowed to dry, the porous collagen glycosaminoglycan-calcium phosphate blocks were placed to the gel in the configuration shown (see Figure 2). As described above, the process involved the partial wetting of the porous material with the collagen/chondroitin-6-sulfate gel such WO 2011/107807 PCT/GB2011/050439 25 that the pores were partially filled in a thin layer at the interface thus allowing a mechanically strong bond to be made between the porous material and the non porous material. The biomaterial was then allowed to air dry with minimal distortion of the structure. Cross-linking - via the application of a dehydrothermal treatment of 5 1050C at 150 mTorr for three days - was used to further enhance the mechanical strength of the collagen-GAG bond in the implant. The resulting implant resembles a bone-patellar-bone or anterior cruciate ligament configuration. The fabrication process can be used to generate biomaterials comprising porous 10 blocks bonded to a non-porous extruded collagen sheet, as shown in Figure 3. The depicted biomaterial (50) comprises non-porous region (60) and porous region (70). Non-porous region (60) comprises an extruded collagen sheet (10) and porous region (70) comprises collagen and a glycosaminoglycan (30). The crosslinked porous region (70) is bonded to the extruded collagen sheet (10, 60) using a bonding 15 layer of adhesive collagen gel (not shown). This material was fabricated as detailed below. An extruded collagen film was used as the substrate for the attachment of a porous collagen sheet to enable the assembly of a scaffold comprising both an impermeable 20 collagen sheet and a porous collagen/GAG sheet. The collagen sheet was extruded as per any of a number of industrial processes for the production of collagen sheet having a thickness of approximately 0.5 mm. The fabrication procedure initially involved the hydration of the collagen sheet with 50 pL per cm 2 of 1% w/v collagen gel. The hydrated sheet was laid flat on a Teflon (RTM) substrate to minimise 25 distortion and maintain planarity. A porous crosslinked collagen/GAG layer was then laid onto the extruded collagen sheet and the gel was allowed to partially hydrate the surface of the porous collagen/GAG layer. The assembled biomaterial was then allowed to air dry with minimal distortion to the physical shape and dimensions of the WO 2011/107807 PCT/GB2011/050439 26 components. The resulting bonded biomaterial comprised a substantially impermeable collagen sheet, a collagen/GAG bonding layer of approximately 50 microns in thickness and a porous collagen/GAG scaffold of approximately 1 mm in thickness, as shown in Figure 3b. This material can subsequently be cross-linked 5 using physical or chemical cross-linking methodologies, as described previously. The bonding together of a porous collagen-based material with an extruded collagen sheet creates a biomaterial having a substantially impermeable layer which enables the porous layer to be loaded with species such as cells, proteins or other macromolecular components without their leakage into the surrounding environment 10 after delivery. The extruded collagen sheet is of sufficient mechanical strength to support tensile loads of greater than 5 N. This mechanical strength enables the sheet to be attached to soft tissue via a variety of orthopaedic fixation techniques including, but not limited to, suturing, tacking, use of darts, use of composite devices such as devices comprising sutures and polymeric tabs or buttons, suture passing devices, 15 bioadhesives such as fibrin glues, techniques involving the induction of fibrin clots or techniques based on the formation of adhesives from other autologous body fluids. Combining porous and non-porous collagen-based materials using the process of the invention also enables the production of a biomaterial which can be used as a 20 stabilised plug, whereby an overlap of the non-porous material provides structural stabilisation of the porous material when it is inserted into a defect site. Examples of the defect site for which this format is most applicable includes (i) cartilage defects, (ii) tooth extraction sockets, (iii) skin injury and (iv) meniscal defect. 25 Figure 4a depicts a sheet of biomaterial (50) comprising multiple different shapes and sizes of porous collagen (30, 70) on an extruded collagen sheet (10, 60) such that the individual components can be selected via cutting out individual pieces or can be used as an assembly to provide porous scaffold into multiple proximate sites. The WO 2011/107807 PCT/GB2011/050439 27 porous regions (70) are bonded to the extruded collagen sheet using a bonding layer of adhesive collagen gel (not shown). A schematic detailing how this biomaterial may be applied into a soft tissue defect site (80) is shown in Figure 4b. 5 Figures 5a show a schematic detailing a meniscal defect filling device (100) according to the present invention for inserting into a defect in the meniscus (130). The defect site is a resected meniscus with an intact outer meniscal rim. The porous section (120) of the device (100) is formed so as to fit into the defect site of the meniscus (130) and is attached to the non-porous part (110) which folds around the 10 meniscus (130). The implant (100) can be fixed into place by fixing means such as sutures (140). Other fixing means may also be used such as tacking, use of darts, use of composite devices such as devices comprising sutures and polymeric tabs or buttons, suture passing devices, bioadhesives such as fibrin glues, techniques involving the induction of fibrin clots or techniques based on the formation of 15 adhesives from other autologous body fluids or any other means known to the person skilled in the art. Fig 5b shows a cross-section at the meniscus (3)) with the implant (100) fixed in place by sutures (140) at the defect site. A further application of the present invention may be as an arterial closure device as 20 illustrated in the Figure 6a schematic. The arterial closure device (200) is formed of a non-porous part (210) and a porous part (220) according to the present invention. The porous part (220) is designed to fit into the artery (230) and the non-porous part (210) is designed to be flexible enough to wrap around the external surface of the arterial wall in order to provide closure. Once the device (200) is in place, it can be 25 fixed to the artery (230) by sutures (240). Other appropriate fixing means may also be used such as tacking, use of darts, use of composite devices such as devices comprising sutures and polymeric tabs or buttons, suture passing devices, bioadhesives such as fibrin glues, techniques involving the induction of fibrin clots or WO 2011/107807 PCT/GB2011/050439 28 techniques based on the formation of adhesives from other autologous body fluids.. Figure 6b shows a cross-section of the arterial closure device (200) in situ. In summary the applicant has developed a fabrication process capable of producing 5 novel formats of biomaterials advantageously having both porosity and mechanical strength. The process relies on the use of a bonding layer of gel comprising collagen to join non-porous and porous collagen-based materials. The hydration of the materials used in the process and the drying of the resulting biomaterial are tightly controlled to maintain the required porosity and the structure/shape of the 10 biomaterial. Physical confinement may be used in the drying to impose three dimensional structure to the biomaterial without distortion of the porous component during the drying process. The process preferably comprises a cross-linking step which does not result in the production of potentially cytotoxic end- or by-products (which ordinarily require removal via subsequent washing steps). The chemistry of 15 the gel may be catered to the type of cross-linking employed. This process is substantially superior to other methods of construction, such as freeze drying fully dense materials, casting in a collagen gel or mechanical integration where much of the structure and properties of the individual components are lost. In particular, the invention enables the integration of an aligned dense non-porous collagen material, 20 such as a fibre or aligned sheet, with a porous material, thus mimicking the structure of the bone-tendon or bone-ligament interface.

Claims

1. A process for fabricating a biomaterial, comprising a) joining a porous collagen based-material with a non-porous collagen based 5 material by applying a controlled amount of a bonding layer of a gel comprising collagen to a bonding surface of the non-porous collagen based-material, and contacting a surface of the porous collagen based-material with the gel applied to the bonding surface to partially hydrate a section of the porous material at the interface between the materials; 10 b) drying the gel to dry to bond the materials together; and c) cross-linking the collagens in the bonding layer.

2. The process of claim 1 wherein in drying step (b) the structure/shape of the materials is substantially retained without distortion. 15

3. The process as claimed in any previous claim wherein step (b) comprises air drying.

4. The process as claimed in claim 3, wherein the temperature and humidity of 20 the environment surrounding the biomaterial are controlled to control the drying rate.

5. The process as claimed in any previous claim wherein the amount of gel applied in the bonding layer is between 50-500 pL cm-2. 25

6. The process as claimed in any previous claim characterised in that the gel is acidic or alkaline prior to being applied to the bonding surface.

7. The process as claimed in claim 6 wherein the gel gelates at neutral pH. WO 2011/107807 PCT/GB2011/050439 30

8. The process as claimed in claim 7 wherein the pH of the gel is neutralised upon application to the bonding surface. 5

9. The process as claimed in any previous claim wherein the gel comprises 0.1 2% wt/vol collagen.

10. The process as claimed in any previous claim wherein the gel further comprises a glycosaminoglycan selected from the group consisting of: chondroitin 4 10 sulfate, chondroitin 6-sulfate, keratan sulfate, dermatan sulfate, heparan sulfate, and hyaluronic acid.

11. The process as claimed in claim 10 wherein the gel comprises from 0.01 to 12 wt% glycosaminoglycan. 15

12. The process as claimed in any previous claim wherein the composition of the gel is the same as the composition of the porous and/or non-porous collagen-based material. 20

13. The process as claimed in any one of claims 10-12 wherein the concentration of the collagen and GAG in the gel is the same as the concentration of the collagen and any GAG in the porous collagen-based material.

14. The process as claimed in any one of claims 2-13 wherein distortion is 25 minimised by using only sufficient gel to ensure bonding of the materials. WO 2011/107807 PCT/GB2011/050439 31

15. The process as claimed in any one of claims 2-14 wherein the structure/shape is retained by constraining the biomaterial in a cage, mould, press or frame to minimise structural distortion as it dries. 5

16. The process as claimed in any one of claims 2-15 wherein the structure/shape is retained by sandwiching the biomaterial between rigid sheets as it dries.

17. The process as claimed in any one of claims 2-16 wherein the 10 structure/shape is retained by adhering a surface other than the bonding surface of the non-porous material to a substrate.

18. The process as claimed in any previous claim wherein cross-linking step (c) comprises a physical cross-linking treatment. 15

19. The process as claimed in any previous claim wherein cross-linking step (c) comprises a dehydrothermal treatment applied to the dried biomaterial to provide a condensation reaction which bonds amine and carboxylic acid groups.

20 20. The process as claimed in any previous claim wherein cross-linking step (c) occurs as the pH of the gel neutralises after application causing fibrillogenesis in the gel.

21. The process as claimed in any previous claim wherein cross-linking step (c) 25 comprises UV treatment.

22. The process as claimed in claim 21 wherein the gel further comprises hydroxyl containing components which optimise the UV treatment. WO 2011/107807 PCT/GB2011/050439 32

23. The process as claimed in any previous claim wherein cross-linking step (c) comprises the use of a vapour phase chemical cross-linking agent which does not result in the formation of non-volatile side products. 5

24. The process as claimed in claim 23 wherein the vapour phase chemical cross-linking agent is selected from the group consisting of: glutaraldehyde, formaldehyde, and hexamethyldiisocyanate 10

25. The process as claimed in any previous claim wherein the gel further comprises components having reactive groups that react with the non-porous collagen-based material and the porous collagen-based material to achieve cross linking without the release of side products, the components being selected from the group consisting of: Aldehyde functionalised (sodium periodate activated), NHS 15 activated esters, Triazine activated collagen and Epoxide functionalised collagen.

26. The process as claimed in any previous claim wherein one or more pieces or regions of non-porous collagen-based material are joined to one or more pieces or regions of porous collagen-based material. 20

27. The process as claimed in any previous claim wherein >95% of the original porosity of the porous collagen-based material is retained.

28. A fabricated biomaterial comprising porous and non-porous collagen-based 25 materials bonded with a bonding layer of dried gel comprising collagen, wherein the collagens in the bonding layer are cross-linked. WO 2011/107807 PCT/GB2011/050439 33

29. The fabrication process or biomaterial as claimed in any previous claim wherein the bonding layer is 50-100 pm in thickness.

30. A biomaterial as claimed in claim 29 or claim 30 wherein the collagen in the 5 porous and/or non-porous collagen-based materials is cross-linked.

31. A biomaterial as claimed in any one of claims 28-30 wherein the porous collagen-based material has >95% of its original porosity. 10

32. A biomaterial as claimed in any one of claims 28-31 wherein the collagen is present in the material in an amount of from 5 to 90 (dry) wt%, or 15 to 60 (dry)wt%, or 20 to 40 (dry) wt%.

33. The fabrication process or biomaterial as claimed in any previous claim 15 wherein the porous and/or non-porous collagen-based material comprises other biopolymeric components selected from the group consisting of glycosaminoglycans, proteoglycans, or proteins.

34. The fabrication process or biomaterial as claimed in claim 33 wherein one or 20 more glycosaminoglycans are present in the material in an amount of from 0.01 to 12 (dry)wt%, or 1 to 5.5 (dry) wt%, or 1.8 to 2.3 (dry) wt%.

35. The fabrication process or biomaterial as claimed in claim 34 wherein the glycosaminoglycan is selected from the group consisting of: chondroitin 4-sulfate, 25 chondroitin 6-sulfate, keratan sulfate, dermatan sulfate, heparan sulfate, hyaluronic acid or chitosan. WO 2011/107807 PCT/GB2011/050439 34

36. The fabrication process or biomaterial as claimed in any one of claims 33-35 wherein the collagen and the glycosaminoglycan are cross-linked.

37. The fabrication process or biomaterial as claimed in claim 33 wherein the 5 proteoglycan is decorin.

38. The fabrication process or biomaterial as claimed in claim 33 wherein the protein is selected from the group consisting of: elastin and resilin. 10

39. The fabrication process or biomaterial as claimed in any previous claim wherein the porous collagen-based material is unmineralised or mineralised.

40. The fabrication process or biomaterial as claimed in claim 39 wherein the porous collagen-based material comprises a calcium phosphate. 15

41. The fabrication process or biomaterial as claimed in claim 40 wherein the calcium phosphate is selected from the group consisting of: brushite, octacalcium phosphate, apatite, hydroxyapatite, P-tricalcium phosphate, biphasic calcium phosphate, substituted calcium phosphate, silicate-substituted calcium phosphate, 20 silicate-substituted hydroxyapatite, and silicate-substituted tricalcium phosphate.

42. The fabrication process or biomaterial as claimed in any previous claim wherein the porous collagen-based material comprises a co-precipitate of collagen and glycosaminoglycan or calcium phosphate. 25

43. The fabrication process or biomaterial as claimed in any previous claim wherein the porous collagen-based material comprises a triple co-precipitate of collagen, glycosaminoglycan and calcium phosphate. WO 2011/107807 PCT/GB2011/050439 35

44. The fabrication process or biomaterial as claimed in any previous claims wherein one or more glycosaminoglycans are present in the material in an amount of from 0.01 to 12 (dry)wt%, or 1 to 5.5 (dry) wt%, or 1.8 to 2.3 (dry) wt%. 5

45. The fabrication process or biomaterial as claimed in any previous claims wherein the non-porous collagen-based material comprises an extruded collagen sheet. 10

46. The fabrication process or biomaterial as claimed in any previous claim wherein the non-porous collagen-based material comprises a bundle of extruded collagen fibres.

47. The fabrication process or biomaterial as claimed in any previous claim 15 wherein the porous collagen-based material comprises a porous collagen scaffold and the non-porous collagen-based material comprises aligned collagen fibres.

48. The fabrication process or biomaterial as claimed in any previous claim wherein the biomaterial comprises multiple regions of porous and/or nonporous 20 collagen-based materials.

49. The fabrication process or biomaterial as claimed in claim 48 wherein the biomaterial comprises non-porous aligned collagen fibres having a porous mineralised collagen-based material at each end. 25

50. The fabrication process or biomaterial as claimed in claim 49 wherein the biomaterial simulates a bone-tendon insertion structure known as Sharpey's Fibres, WO 2011/107807 PCT/GB2011/050439 36 the biomaterial comprising substantially parallel non-porous collagen fibres and porous mineralised collagen-based material at each end.

51. The fabrication process or biomaterial as claimed in any one of claims 1-38 5 wherein the biomaterial is an unmineralised porous patch comprising a non-porous collagen membrane bonded to a porous collagen-based material comprising collagen and a GAG.

52. The fabrication process or biomaterial as claimed in claim 51 wherein the 10 unmineralised porous patch comprises more than one region of the porous collagen based material.

53. The fabrication process or biomaterial as claimed in any previous claim wherein the non-porous collagen-based material acts as a barrier to the transport of 15 cells, proteins, and small molecules out of the porous collagen-based material.

54. The fabrication process or biomaterial as claimed in any previous claim wherein the non-porous collagen-based material overlaps the porous collagen-based material to provide a flap to enable fixation of the device in a defect site. 20

55. An implant comprising the fabricated biomaterial as claimed in any one of claims 28-54.

56. An implant or biomaterial as claimed in any one of claims 28-55, further 25 comprising cells.

57. A synthetic cartilage, bone, ligament, tendon, meniscus, periodontal tissue, dentine, enamel, intervertebral disc, annulus fibrosus, or nucleus pulposus implant, WO 2011/107807 PCT/GB2011/050439 37 or graft, substitute, scaffold, filler, coating or cement comprising a biomaterial or implant as claimed in any one of claims 28-55.

58. Use of a collagen gel to bond porous and non-porous collagen-based 5 materials.

59. A method of treatment of a defect in a target tissue of a patient comprising: taking a biomaterial or implant as claimed in any one of claims 28-56 and inserting the material into the defect site of the patient. 10

60. A method of organ or tissue engineering in a patient, comprising the step of replacing a target tissue in the patient with a biomaterial or implant as claimed in any one of claims 28-56. 15

61. Use of a biomaterial or implant according as claimed in any one of claims 28 56 to treat a defect in a target tissue of a patient.

62. Use of a biomaterial or implant as claimed in any one of claims 28-56 in tissue engineering of a target tissue of a patient. 20

63. The method or use as claimed in any one of claims 59-62 wherein the target tissue is selected from the group consisting of: cartilage, bone, ligament, tendon, artery, Sharpey's fibres, meniscus, periodontal tissue, dentine, enamel, intervertebral discs, annulus fibrosus, and nucleus pulposus. 25

64. The method or use as claimed in any one of claims 59-63 wherein the patient is a mammal or a non-human mammal. WO 2011/107807 PCT/GB2011/050439 38

65. The method or use as claimed in claim 64 wherein the patient is a human, dog, camel, or horse.

66. A method or use as claimed in any one of claims 59 to 65 wherein the biomaterial 5 is fixed at the defect site by a fixing means.

67. A method or use as claimed in claim 66 wherein the fixing means is selected from sutures, tacks, darts, polymeric tabs, bioadhesives, fibrin glue, fibrin clot forming means, adhesives from autologous body fluids or composites comprising one or 10 more of the fixing means.

68. A kit of parts comprising a biomaterial or implant as claimed in any one of claims 28-56, in combination with a delivery device. 15

69. The kit as claimed in claim 68 further comprising a plurality of biomaterials or implants or delivery devices, or combinations thereof.

70. A meniscal defect implant comprising the biomaterial according to any one of claims 28 to 54. 20

71. A meniscal defect implant according to claim 70 wherein the implant is fixed to the meniscus by means of sutures, tacks, darts, polymeric tabs, bioadhesives, fibrin glue, fibrin clot forming means, adhesives from autologous body fluids or composites comprising one or more of the fixing means. 25

72. A meniscal defect implant according to claim 70 or 71 further comprising cells. WO 2011/107807 PCT/GB2011/050439 39

73. An arterial closure device comprising the biomaterial according to any one of claims 28 to 54.

74. An arterial closure device according to claim 73 wherein the device is fixed to an 5 artery by means of sutures, tacks, darts, polymeric tabs, bioadhesives, fibrin glue, fibrin clot forming means, adhesives from autologous body fluids or composites comprising one or more of the fixing means.

75. An arterial closure device according to claim 73 or 74 further comprising cells.